Arcus Biosciences Announces New Employment Inducement Grants
September 10 2020 - 4:10PM
Business Wire
Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused
biopharmaceutical company working to create best-in-class cancer
therapies, today announced that the Compensation Committee of the
Company’s Board of Directors granted six new employees options to
purchase a total of 120,500 shares of the Company’s common stock at
an exercise price per share of $20.71, which was the closing price
on September 8, 2020. The stock options were granted pursuant to
the Company’s 2020 Inducement Plan, which was approved by the
Company’s Board of Directors in January 2020 pursuant to the
“inducement exception” under NYSE Listed Company Manual Rule
303A.08.
About Arcus Biosciences
Arcus Biosciences is an oncology-focused biopharmaceutical
company leveraging its deep cross-disciplinary expertise to create
highly differentiated therapies and to develop a broad portfolio of
novel combinations addressing significant unmet needs. Arcus
currently has four molecules in clinical development:
Etrumadenant (AB928), the first and only dual A2a/A2b
adenosine receptor antagonist in the clinic, is being evaluated in
multiple Phase 1b/2 studies across different indications, including
prostate, colorectal, non-small cell lung, pancreatic and
triple-negative breast cancers. AB680, the first
small-molecule CD73 inhibitor in the clinic, is in Phase 1
development for first-line treatment of metastatic pancreatic
cancer in combination with zimberelimab and
gemcitabine/nab-paclitaxel. Domvanalimab (AB154), an
anti-TIGIT monoclonal antibody and new potential immuno-oncology
backbone therapy, is in a three-arm randomized Phase 2 study for
first-line treatment of PD-L1-high metastatic non-small cell lung
cancer evaluating zimberelimab monotherapy, AB154 with zimberelimab
and AB154 plus AB928 with zimberelimab. Zimberelimab
(AB122), Arcus’s anti-PD-1 monoclonal antibody, is also being
evaluated in a Phase 1b study as monotherapy for cancers with no
approved anti-PD-1 treatment options, and in various combinations
across the portfolio. For more information about Arcus Biosciences,
please visit www.arcusbio.com.
Source: Arcus Biosciences
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200910005298/en/
Katherine Bock (510) 694-6231 kbock@arcusbio.com
Arcus Biosciences (NYSE:RCUS)
Historical Stock Chart
From Apr 2024 to May 2024
Arcus Biosciences (NYSE:RCUS)
Historical Stock Chart
From May 2023 to May 2024